Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 1/20 | 0.34 |
| ▸ | MAP2K1 | Q02750 | 10/20 | 0.33 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.32 |
| ▸ | NQO2 | P16083 | 1/20 | 0.32 |
| ▸ | MAP2K2 | P36507 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | PIM1 | P11309 | 1/20 | 0.30 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.30 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.30 |
| ▸ | EGFR | P00533 | 1/20 | 0.30 |
| ▸ | RET | P07949 | 1/20 | 0.30 |
| ▸ | KIF5B | P33176 | 1/20 | 0.30 |
| ▸ | KDR | P35968 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3424020 | 0.84 | DGAT1 (0.32) | DGAT1PIM1PIM3PIM2 | |
| SCHEMBL6205792 | 0.80 | MAP2K1 (0.43) | DGAT1MAP2K1MAP2K2PIM1PIM3 | |
| SCHEMBL3426225 | 0.79 | MAP2K1 (0.50) | MAP2K1ABCB11NQO2MAP2K2MEN1 | |
| SCHEMBL3425471 | 0.75 | MAP2K1 (0.47) | MAP2K1ABCB11NQO2MAP2K2MEN1 | |
| SCHEMBL3426067 | 0.74 | MAP2K1 (0.46) | MAP2K1ABCB11NQO2MAP2K2MEN1 | |
| SCHEMBL391367 | 0.73 | MAP2K1 (0.59) | MAP2K1ABCB11NQO2MAP2K2 | |
| SCHEMBL5474880 | 0.73 | DGAT1 (0.40) | DGAT1MAP2K1MAP2K2EGFRRET | |
| SCHEMBL5404404 | 0.72 | MAP2K1 (0.36) | DGAT1MAP2K1ABCB11NQO2MAP2K2 | |
| SCHEMBL1041920 | 0.69 | MAP2K1 (0.35) | DGAT1MAP2K1MAP2K2PIM1PIM3 | |
| SCHEMBL30536473 | 0.69 | IDO1 (0.34) | DGAT1PIM1PIM3PIM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1689233-B1 | BICYCLIC INHIBITORS OF MEK | ARRAY BIOPHARMA INC (US) | 2012-07-04 | — | — | EP | disclosed |
| EP-1689233-B1 | BICYCLIC INHIBITORS OF MEK | ARRAY BIOPHARMA INC (US) | 2012-07-04 | — | — | EP | disclosed |
| US-7772234-B2 | 7-(2,4-Dichlorophenylamino)-8-fluoro-4-methyl-cinnoline-6-carboxylic acid (2-hydroxyethoxy)-amide; mitogen activated protein, extracellular signal regulated kinase, kinase inhibitor; cancer and inflammation | ARRAY BIOPHARMA INC. (US) | 2010-08-10 | — | — | US | disclosed |
| US-7772234-B2 | 7-(2,4-Dichlorophenylamino)-8-fluoro-4-methyl-cinnoline-6-carboxylic acid (2-hydroxyethoxy)-amide; mitogen activated protein, extracellular signal regulated kinase, kinase inhibitor; cancer and inflammation | ARRAY BIOPHARMA INC. (US) | 2010-08-10 | — | — | US | disclosed |
| US-7772234-B2 | 7-(2,4-Dichlorophenylamino)-8-fluoro-4-methyl-cinnoline-6-carboxylic acid (2-hydroxyethoxy)-amide; mitogen activated protein, extracellular signal regulated kinase, kinase inhibitor; cancer and inflammation | ARRAY BIOPHARMA INC. (US) | 2010-08-10 | — | — | US | disclosed |
| EP-1689233-A4 | BICYCLIC INHIBITORS OF MEK AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC (US) | 2007-08-29 | — | — | EP | disclosed |
| EP-1689233-A2 | BICYCLIC INHIBITORS OF MEK AND METHODS OF USE THEREOF | Array Biopharma, Inc. (US) | 2006-08-16 | — | — | EP | disclosed |
| US-20050130976-A1 | Bicyclic inhibitors of MEK and methods of use thereof | ARRAY BIOPHARMA INC. | 2005-06-16 | — | — | US | disclosed |
| WO-2005051302-A2 | BICYCLIC INHIBITORS OF MEK AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC. (US) | 2005-06-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050130976-A1 | Bicyclic inhibitors of MEK and methods of use thereof | NRAS, BRAF, RAF1 | DGAT1 3343/4885MAP2K1 33/4885ABCB11 1567/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.